Health pathway intervention for people with long-term COVID-19 symptoms
Effect of a Health Pathway for People With Persistent Symptoms Covid-19
This study is testing a personalized support program for people with long-term COVID-19 symptoms to see if it helps improve their health and well-being.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne Academic / other |
| Locations | 3 sites (Lyon and 2 other locations) |
| Trial ID | NCT05787366 on ClinicalTrials.gov |
What this trial studies
This study focuses on individuals experiencing persistent symptoms following COVID-19 infection, which can significantly affect their quality of life. It aims to implement a personalized multifactorial intervention alongside usual care and follow-up by a nurse to address the physical, psychological, and social needs of these patients. By providing tailored support and management strategies, the study seeks to alleviate symptoms and improve overall well-being. Participants will be recruited from partner healthcare structures and will receive comprehensive care over an extended period.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals who have been infected with COVID-19 and are experiencing persistent symptoms for more than 12 weeks.
Not a fit: Patients who may not benefit from this study include those with severe cognitive impairment or those who refuse to participate.
Why it matters
Potential benefit: If successful, this intervention could significantly enhance the quality of life for patients suffering from long-term COVID-19 symptoms.
How similar studies have performed: Other studies have shown promise in addressing long-term COVID-19 symptoms through personalized interventions, indicating that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria * Persons who have been infected with Covid-19. * Person with persistent clinical signs of Covid-19 for more than 12 weeks, referred by one of the partner structures of the project. The persistent signs of Covid-19 are: fatigue which can be severe, neurological disorders neurological disorders (cognitive, sensory, headaches), cardio-thoracic disorders (pain and chest tightness, tachycardia, dyspnea, cough) and disorders of smell and taste. Pain, digestive disorders and skin disorders are also common. * Person who has agreed to participate and has given informed consent to participate in the study Exclusion Criteria: * Refused to participate in the study * Person under legal protection * Person with severe cognitive impairment
Where this trial is running
Lyon and 2 other locations
- Urps Medecins Libéraux Auvergne-Rhône-Alpes — Lyon, France (Not_yet_recruiting)
- Chu Saint-Etienne — Saint Etienne, France (Recruiting)
- DAC Loire — Saint-Étienne, France (Not_yet_recruiting)
Study contacts
- Principal investigator: Frédéric ROCHE, PhD — CHU de Saint Etienne
- Study coordinator: Caroline DUPRE, PhD
- Email: caroline.dupre@univ-st-etienne.fr
- Phone: 0477816352
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.